---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274124"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:16:45.750203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q3 net loss $14.5M; cash $142.1M; ACR-368 shows early clinical activity

## Summary
- Net loss of $14.5M in Q3 2023 vs $9.2M in Q3 2022; R&D expenses $10.3M, G&A $5.9M.
- Cash and marketable securities $142.1M as of Sept 30, 2023; expected to fund operations into H2 2025.
- ACR-368: initial clinical activity observed in OncoSignature-positive patients across ovarian, endometrial, urothelial cancers; mature data H1 2024.
- ACR-2316 dual WEE1/PKMYT1 inhibitor: IND submission planned Q4 2024; designed for superior single-agent activity via AP3 platform.
- Two posters at AACR-NCI-EORTC conference validate ACR-368 OncoSignature assay with 47-58% ORR in tumor biopsies.

## SEC filing metadata
- accession: 0001193125-23-274124
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/0001193125-23-274124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/d591379d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274124
- JSON: https://secwatch.observer/filing/0001193125-23-274124.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274124.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $14.5 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $14.5 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/0001193125-23-274124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.